Impact of Different Atorvastatin Doses on Platelet Reactivity in Patients With Acute ST-elevation Myocardial Infarction
10.3969/j.issn.1000-3614.2017.01.007
- VernacularTitle:不同剂量阿托伐他汀对急性ST段抬高型心肌梗死患者血小板反应性的影响
- Author:
Xiaorong XU
;
Kuibao LI
;
Pan WANG
;
Yu LIU
;
Changlin LU
;
Xinchun YANG
;
Zhongsu YANG
- Keywords:
Myocardial infarction;
Lipid-lowering drngs;
Platelet
- From:
Chinese Circulation Journal
2017;32(1):26-30
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the impact of different atorvastatin doses on platelet function and highreactivity in patients with acute ST-elevation myocardial infarction (STEMI) after emergent percutaneouscoronary intervention (PCI) therapy.
Methods:A total of 120 STEMI patients with emergent PCI therapy were randomly divided into 2 groups:Standard group, the patients received atorvastatin 20 mg/day and Intensive group, the patientsreceived atorvastatin 40 mg/day, all patients were treated for 7 days. n=60 in each group. Blood lipids and biochemistry were examined before PCI and 7 days after atorvastatin treatment respectively;platelet fibrin clot strength induced by ADP (MAADP), AA and ADP induced platelet inhibition rate were measured by thrombelastography (TEG) test.
Results: With 7 days treatment, compared with Standard group, Intensive group showed decreased MAADP (38.40±17.40) mm vs (45.70±14.50) mm, P<0.05. On day 7 of atorvastatin treatment, compared with Standard group, Intensive group had reduced occurrence rate of high ADP reactivity (18.3%vs 31.7%), P<0.05. The occurrence rate of high AA reactivity was similar between 2 groups (13.3%vs 18.3%), P>0.05. The patients were followed-up for 3 months and the end point events including unstable angina, non-fatal MI, in-stent restenosis, in-stent thrombosis, and cardiovascular death or target vessel revascularization were similar between 2 groups, P>0.05.
Conclusion: Early stage and short term administration of high dose atorvastatin could obviously inhibit platelet activity in STEMI patients after emergent PCI;such intensive atorvastatin treatment had no reduction on end point events in 3 months follow-up period.
